Bristol-Myers Squibb's Q1 2026 results came in roughly as expected, with the stock closing up 1.1% post-earnings. Management highlighted solid year-over-year growth in the key portfolio and reiterated progress in R&D and pipeline milestones.

• Growth portfolio sales increased 9% year-over-year, with broad contributions from multiple early-life-cycle assets.
• Eliquis performed in line with the company's previously provided range.
• Regulatory and clinical milestones included positive Phase III results for key pipeline assets (iberdomide, mozigimide, and ADC candidates), with full data presentations and regulatory submissions planned for later in the year.
• Management reiterated focus on improving R&D productivity, targeting faster lead molecule identification and a 30% reduction in development cycle times.
• The company remains on track to deliver its remaining $2 billion in cost savings by end of 2027, supporting ongoing investment in R&D and business development.